Merck to invest 100 million Euros in biosimilars



Recognising biosimilars as new sources of growth, Germany’s Merck KGaA is gearing up for more acquisitions, as well as searching for pharmaceutical in-licensing deals and planning to invest around Euros 100 million in biosimilars. The move comes in the wake of news that Merck’s top-selling drug Rebif (interferon beta-1a), an injectable multiple sclerosis treatment, is gradually being replaced by new orally administered drugs such as Biogen Idec’s Tecfidera (dimethyl fumarate).

Read the source article at

About the Author

Leave a Reply